Study approvals and registration
The Brazilian study protocol was approved by the Institute of Biomedical
Sciences (ICB) Ethics Committee, Sao Paulo (ID 38660320.0.0000.5467).
The Argentinian study protocol was approved by the Independent Ethics
Committee for Clinical Pharmacology Trials, Buenos Aires (ID N 3183).
The Egyptian study protocol was approved by the Ethics committee,
Faculty of Medicine, Alexandria University (ID 2158_11456_4737). Each
contributing study is also registered individually as follows:
PACTR202007606032743 (Egypt), NCT04530578 (Argentina). Registration and
ethics approval are pending in other countries.
Keywords: COVID-19, ARDS, SARS, inhaled heparin, nebulised heparin,
unfractionated heparin, SARS-CoV-2, respiratory failure, pandemic,
randomised controlled trial, meta-trial